AlzeCure ACD856 QuantumCell Deal: $2.2B Risk Transfer in Alzheimer’s
Witfire Elite · Licensing Risk Brief · CNS AlzeCure’s $2.2 Billion NeuroRestore Deal Is a Risk Transfer, Not a Victory AlzeCure did not prove…
Witfire Coverage
Category: Pharma Market Case Studies
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Witfire Elite · Launch Execution · Competitive Strategy Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell. Viridian entered a $1.9 billion…
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-05 FDA Issues CRL to Sobi for NASP: The Agency Rejected the Control…
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Witfire Elite · Competitive Strategy · Japan Pharma Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 4SigHT is formally a long-term observational study.…
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Witfire Elite Oncology Strategy Case Studies Financing Long Read Pharma Market Case Studies Witfire Elite View Revolution Medicines Built a $4.3 Billion Wall Around…
GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy
Witfire Elite Oncology M&A Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View GSK Did Not Simply Buy Nuvalent It Bought…
India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent
Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View India CRO Boom Why Chinese Molecules May Build…
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Iran War Pharma Shock Why India’s API Dependence…
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema is being…
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in India —…